These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26945298)

  • 61. Health Insurers Often Foot Bill When Drug Coupons Are Used.
    Wolinsky H
    Manag Care; 2017 Mar; 26(3):38-39. PubMed ID: 28510519
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Drug expenditure in Ireland 1997-2007.
    Barry M; Molloy D; Usher C; Tilson L
    Ir Med J; 2008; 101(10):299-302. PubMed ID: 19205138
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The pharmaceutical industry--prices and progress.
    Scherer FM
    N Engl J Med; 2004 Aug; 351(9):927-32. PubMed ID: 15329432
    [No Abstract]   [Full Text] [Related]  

  • 64. Patent nonsense: evidence tells of an industry out of social control.
    Mintzberg H
    CMAJ; 2006 Aug; 175(4):374. PubMed ID: 16908900
    [No Abstract]   [Full Text] [Related]  

  • 65. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmaceutical expenditure in Spain: cost and control.
    Lopez Bastida J; Mossialos E
    Int J Health Serv; 2000; 30(3):597-616. PubMed ID: 11109184
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
    Augurzky B; Göhlmann S; Gress S; Wasem J
    Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
    [TBL] [Abstract][Full Text] [Related]  

  • 68. How might the Trans-Pacific Partnership impact on the pharmaceutical sector in Vietnam?
    Binh NH; Anh PN; Phuong NM
    Pharm Pat Anal; 2016 Jul; 5(4):261-70. PubMed ID: 27346326
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Managed Entry Agreements for Pharmaceutical Products in Middle East and North African Countries: Payer and Manufacturer Experience and Outlook.
    Maskineh C; Nasser SC
    Value Health Reg Issues; 2018 Sep; 16():33-38. PubMed ID: 29936067
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Drug pricing and value in oncology.
    Danzon PM; Taylor E
    Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study.
    Armeni P; Jommi C; Otto M
    Eur J Health Econ; 2016 Nov; 17(8):963-977. PubMed ID: 26507643
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The ethics and economics of pharmaceutical pricing.
    Parker-Lue S; Santoro M; Koski G
    Annu Rev Pharmacol Toxicol; 2015; 55():191-206. PubMed ID: 25149920
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Eliminating innovation: how price controls limit access.
    Ingram J
    J Leg Med; 2011 Jan; 32(1):115-28. PubMed ID: 21391059
    [No Abstract]   [Full Text] [Related]  

  • 74. [Is prescription of a therapy costing 150,000 CHF reasonable?].
    Peters S; von Moos R; Thurlimann B
    Rev Med Suisse; 2015 Oct; 11(491):1967-72. PubMed ID: 26672265
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prescription drug prices in Canada.
    Gross D
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2003 Jun; (IB62):1-22. PubMed ID: 12807123
    [No Abstract]   [Full Text] [Related]  

  • 76. Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead.
    Kaltenboeck A
    Value Health; 2020 Apr; 23(4):421-424. PubMed ID: 32327158
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Should the patent system for pharmaceuticals be replaced? A theoretical approach.
    Antoñanzas F; Rodríguez-Ibeas R; Juárez-Castelló CA
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):617-26. PubMed ID: 24934980
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Patent cliff mitigation strategies: giving new life to blockbusters.
    Kakkar AK
    Expert Opin Ther Pat; 2015; 25(12):1353-9. PubMed ID: 26372691
    [TBL] [Abstract][Full Text] [Related]  

  • 79. European Pharmaceutical Pricing and Reimbursement--SMi's 21st Annual Meeting (October 5-6, 2015--London, UK).
    Kibble A; D'Souza P
    Drugs Today (Barc); 2015 Oct; 51(10):609-12. PubMed ID: 26583303
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.
    Wettermark B; Godman B; Andersson K; Gustafsson LL; Haycox A; Bertele V
    Pharmacoeconomics; 2008; 26(7):537-50. PubMed ID: 18563945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.